From: Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis
No | Sex | Age range | Disease duration, years | Skin involvement | ILD | PAH | GI involvement | ANA | Anti-centromere | Anti-scl70 |
---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 40–49 | 20 | Limited | Yes, NSIP | No | GERD | 1:80, nucleolar | Negative | Negative |
2 | 1 | 40–49 | 13 | Diffuse | Yes, NSIP + UIP | Yes | Recurrent paralytic ileus | 1:1280, speckled | Negative | Negative |
3 | 1 | 50–59 | 2 | Diffuse | Yes, UIP | No | GERD | 1:1280, cytoplasmic | Negative | Positive |
4 | 2 | 60–69 | 5 | Diffuse | Yes, NSIP | No | GERD | 1:80, speckled | Negative | Negative |
5 | 1 | 50–59 | 16 | Diffuse | No | No | GERD, scleroderma esophagus | 1:640, speckled | Negative | Negative |